Rui-Hua Xu (Ruihua Xu)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 102

Top Venues

Nature medicine

Cancer communications (London, England)

Nature communications

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Sun Yat-Sen University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Sun Yat-Sen University

China

President / Professor :: Cancer Center

Publications

Feng-Hua Wang, Lin Shen, Weijian Guo, Tian-Shu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yue-Yin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, Fuxiang Zhou, Yanru Qin, Lei Yang, Weidong Mao, Qiu Li, Wenxiang Dai, Wei Li, Shubin Wang, Yong Tang, Dong Ma, Xianli Yin, Yanhong Deng, Ying Yuan, Man Li, Wenwei Hu, Donghui Chen, Guoxin Li, Qiqi Liu, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su, Rui-Hua Xu
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nature medicine (2024)
Shu-Qiang Yuan, Run-Cong Nie, Ying Jin, Cheng-Cai Liang, Yuan-Fang Li, Rui Jian, Xiao-Wei Sun, Ying-Bo Chen, Wen-Long Guan, Zi-Xian Wang, Hai-Bo Qiu, Wei Wang, Shi Chen, Dong-Sheng Zhang, Yi-Hong Ling, Shao-Yan Xi, Mu-Yan Cai, Chun-Yu Huang, Qiu-Xia Yang, Zhi-Min Liu, Yuan-Xiang Guan, Yong-Ming Chen, Weiwei Xiao, Xiong-Wen Tang, Jun-Sheng Peng, Zhou-Wei Zhou, Rui-Hua Xu, Feng-Hua Wang
Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nature medicine (2024)
Akihito Kawazoe, Rui-Hua Xu, Pilar García Alfonso, Maria Passhak, Hao-Wei Teng, Ardaman Shergill, Mahmut Gümüş, Camilla Qvortrup, Sebastian Stinzing, Kathryn Towns, Tae Won Kim, Kai-Keen Shiu, Juan Cundom, Sumitra Ananda, Andrey Lebedinets, Rong Fu, Rishi Jain, David Adelberg, Volker Heinemann, Takayuki Yoshino, Elena Elez Fernandez, null null
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (24) (2024)
Feng-Hua Wang, Ying Jin, Min Wang, Hui-Yan Luo, Wei-Jia Fang, Ying-Nan Wang, Yan-Xing Chen, Run-Jie Huang, Wen-Long Guan, Weiwei Xiao, Yu-Hong Li, Feng-Hua Wang, Xiao-Hua Hu, Yan-Qiao Zhang, Miao-Zhen Qiu, Lu-Lu Liu, Zi-Xian Wang, Chao Ren, De-Shen Wang, Dong-Sheng Zhang, Zhi-Qiang Wang, Wen-Ting Liao, Lin Tian, Qi Zhao, Rui-Hua Xu
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nature medicine 30 (4) (2024)
Feng-Hua Wang, Ying Jin, Min Wang, Hui-Yan Luo, Wei-Jia Fang, Ying-Nan Wang, Yan-Xing Chen, Run-Jie Huang, Wen-Long Guan, Weiwei Xiao, Yu-Hong Li, Feng-Hua Wang, Xiao-Hua Hu, Yan-Qiao Zhang, Miao-Zhen Qiu, Lu-Lu Liu, Zi-Xian Wang, Chao Ren, De-Shen Wang, Dong-Sheng Zhang, Zhi-Qiang Wang, Wen-Ting Liao, Lin Tian, Qi Zhao, Rui-Hua Xu
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nature medicine 30 (4) (2024)
Akihito Kawazoe, Rui-Hua Xu, Pilar García Alfonso, Maria Passhak, Hao-Wei Teng, Ardaman Shergill, Mahmut Gümüş, Camilla Qvortrup, Sebastian Stinzing, Kathryn Towns, Tae Won Kim, Kai-Keen Shiu, Juan Cundom, Sumitra Ananda, Andrey Lebedinets, Rong Fu, Rishi Jain, David Adelberg, Volker Heinemann, Takayuki Yoshino, Elena Elez Fernandez, null null
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (24) (2024)
Akihito Kawazoe, Rui-Hua Xu, Pilar García Alfonso, Maria Passhak, Hao-Wei Teng, Ardaman Shergill, Mahmut Gümüş, Camilla Qvortrup, Sebastian Stinzing, Kathryn Towns, Tae Won Kim, Kai-Keen Shiu, Juan Cundom, Sumitra Ananda, Andrey Lebedinets, Rong Fu, Rishi Jain, David Adelberg, Volker Heinemann, Takayuki Yoshino, Elena Elez Fernandez, null null
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Shu-Qiang Yuan, Run-Cong Nie, Ying Jin, Cheng-Cai Liang, Yuan-Fang Li, Rui Jian, Xiao-Wei Sun, Ying-Bo Chen, Wen-Long Guan, Zi-Xian Wang, Hai-Bo Qiu, Wei Wang, Shi Chen, Dong-Sheng Zhang, Yi-Hong Ling, Shao-Yan Xi, Mu-Yan Cai, Chun-Yu Huang, Qiu-Xia Yang, Zhi-Min Liu, Yuan-Xiang Guan, Yong-Ming Chen, Weiwei Xiao, Xiong-Wen Tang, Jun-Sheng Peng, Zhou-Wei Zhou, Rui-Hua Xu, Feng-Hua Wang
Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nature medicine (2024)
Miao-Zhen Qiu, Do-Youn Oh, Ken Kato, Tobias Arkenau, Josep Tabernero, Marcia Cruz Correa, Anastasia V Zimina, Yuxian Bai, Jianhua Shi, Keun-Wook Lee, Jufeng Wang, Elena Poddubskaya, Hongming Pan, Sun Young Rha, Ruixing Zhang, Hidekazu Hirano, David Spigel, Kensei Yamaguchi, Yee Chao, Lucjan Wyrwicz, Umut Disel, Roberto Pazo Cid, Lorenzo Fornaro, Ludovic Evesque, Hongwei Wang, Yaling Xu, Jiang Li, Tao Sheng, Silu Yang, Liyun Li, Markus Moehler, Rui-Hua Xu, null null
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ (Clinical research ed.) 385 (2024)
Shu-Qiang Yuan, Run-Cong Nie, Ying Jin, Cheng-Cai Liang, Yuan-Fang Li, Rui Jian, Xiao-Wei Sun, Ying-Bo Chen, Wen-Long Guan, Zi-Xian Wang, Hai-Bo Qiu, Wei Wang, Shi Chen, Dong-Sheng Zhang, Yi-Hong Ling, Shao-Yan Xi, Mu-Yan Cai, Chun-Yu Huang, Qiu-Xia Yang, Zhi-Min Liu, Yuan-Xiang Guan, Yong-Ming Chen, Weiwei Xiao, Xiong-Wen Tang, Jun-Sheng Peng, Zhou-Wei Zhou, Rui-Hua Xu, Feng-Hua Wang
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nature medicine 30 (2) (2024)
Feng-Hua Wang, Ying Jin, Min Wang, Hui-Yan Luo, Wei-Jia Fang, Ying-Nan Wang, Yan-Xing Chen, Run-Jie Huang, Wen-Long Guan, Weiwei Xiao, Yu-Hong Li, Feng-Hua Wang, Xiao-Hua Hu, Yan-Qiao Zhang, Miao-Zhen Qiu, Lu-Lu Liu, Zi-Xian Wang, Chao Ren, De-Shen Wang, Dong-Sheng Zhang, Zhi-Qiang Wang, Wen-Ting Liao, Lin Tian, Qi Zhao, Rui-Hua Xu
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nature medicine (2024)
Miao-Zhen Qiu, Do-Youn Oh, Ken Kato, Tobias Arkenau, Josep Tabernero, Marcia Cruz Correa, Anastasia V Zimina, Yuxian Bai, Jianhua Shi, Keun-Wook Lee, Jufeng Wang, Elena Poddubskaya, Hongming Pan, Sun Young Rha, Ruixing Zhang, Hidekazu Hirano, David Spigel, Kensei Yamaguchi, Yee Chao, Lucjan Wyrwicz, Umut Disel, Roberto Pazo Cid, Lorenzo Fornaro, Ludovic Evesque, Hongwei Wang, Yaling Xu, Jiang Li, Tao Sheng, Silu Yang, Liyun Li, Markus Moehler, Rui-Hua Xu, null null
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ (Clinical research ed.) 385 (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
Shixiang Wang, Chen-Yi Wu, Ming-Ming He, Jia-Xin Yong, Yan-Xing Chen, Li-Mei Qian, Jin-Ling Zhang, Zhao-Lei Zeng, Rui-Hua Xu, Feng-Hua Wang, Qi Zhao
Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer. Nature communications 15 (1) (2024)
Feng-Hua Wang, Lin Shen, Weijian Guo, Tian-Shu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yue-Yin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, Fuxiang Zhou, Yanru Qin, Lei Yang, Weidong Mao, Qiu Li, Wenxiang Dai, Wei Li, Shubin Wang, Yong Tang, Dong Ma, Xianli Yin, Yanhong Deng, Ying Yuan, Man Li, Wenwei Hu, Donghui Chen, Guoxin Li, Qiqi Liu, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su, Rui-Hua Xu
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nature medicine 30 (8) (2024)
Shu-Qiang Yuan, Run-Cong Nie, Ying Jin, Cheng-Cai Liang, Yuan-Fang Li, Rui Jian, Xiao-Wei Sun, Ying-Bo Chen, Wen-Long Guan, Zi-Xian Wang, Hai-Bo Qiu, Wei Wang, Shi Chen, Dong-Sheng Zhang, Yi-Hong Ling, Shao-Yan Xi, Mu-Yan Cai, Chun-Yu Huang, Qiu-Xia Yang, Zhi-Min Liu, Yuan-Xiang Guan, Yong-Ming Chen, Weiwei Xiao, Xiong-Wen Tang, Jun-Sheng Peng, Zhou-Wei Zhou, Rui-Hua Xu, Feng-Hua Wang
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nature medicine 30 (2) (2024)
Feng-Hua Wang, Ying Jin, Min Wang, Hui-Yan Luo, Wei-Jia Fang, Ying-Nan Wang, Yan-Xing Chen, Run-Jie Huang, Wen-Long Guan, Weiwei Xiao, Yu-Hong Li, Feng-Hua Wang, Xiao-Hua Hu, Yan-Qiao Zhang, Miao-Zhen Qiu, Lu-Lu Liu, Zi-Xian Wang, Chao Ren, De-Shen Wang, Dong-Sheng Zhang, Zhi-Qiang Wang, Wen-Ting Liao, Lin Tian, Qi Zhao, Rui-Hua Xu
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nature medicine 30 (4) (2024)
Akihito Kawazoe, Rui-Hua Xu, Pilar García Alfonso, Maria Passhak, Hao-Wei Teng, Ardaman Shergill, Mahmut Gümüş, Camilla Qvortrup, Sebastian Stinzing, Kathryn Towns, Tae Won Kim, Kai-Keen Shiu, Juan Cundom, Sumitra Ananda, Andrey Lebedinets, Rong Fu, Rishi Jain, David Adelberg, Volker Heinemann, Takayuki Yoshino, Elena Elez Fernandez, null null
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (24) (2024)
Feng-Hua Wang, Ying Jin, Min Wang, Hui-Yan Luo, Wei-Jia Fang, Ying-Nan Wang, Yan-Xing Chen, Run-Jie Huang, Wen-Long Guan, Weiwei Xiao, Yu-Hong Li, Feng-Hua Wang, Xiao-Hua Hu, Yan-Qiao Zhang, Miao-Zhen Qiu, Lu-Lu Liu, Zi-Xian Wang, Chao Ren, De-Shen Wang, Dong-Sheng Zhang, Zhi-Qiang Wang, Wen-Ting Liao, Lin Tian, Qi Zhao, Rui-Hua Xu
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nature medicine 30 (4) (2024)
Feng-Hua Wang, Lin Shen, Weijian Guo, Tian-Shu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yue-Yin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, Fuxiang Zhou, Yanru Qin, Lei Yang, Weidong Mao, Qiu Li, Wenxiang Dai, Wei Li, Shubin Wang, Yong Tang, Dong Ma, Xianli Yin, Yanhong Deng, Ying Yuan, Man Li, Wenwei Hu, Donghui Chen, Guoxin Li, Qiqi Liu, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su, Rui-Hua Xu
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nature medicine 30 (8) (2024)
Shixiang Wang, Chen-Yi Wu, Ming-Ming He, Jia-Xin Yong, Yan-Xing Chen, Li-Mei Qian, Jin-Ling Zhang, Zhao-Lei Zeng, Rui-Hua Xu, Feng-Hua Wang, Qi Zhao
Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer. Nature communications 15 (1) (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
Feng-Hua Wang, Ying Jin, Min Wang, Hui-Yan Luo, Wei-Jia Fang, Ying-Nan Wang, Yan-Xing Chen, Run-Jie Huang, Wen-Long Guan, Weiwei Xiao, Yu-Hong Li, Feng-Hua Wang, Xiao-Hua Hu, Yan-Qiao Zhang, Miao-Zhen Qiu, Lu-Lu Liu, Zi-Xian Wang, Chao Ren, De-Shen Wang, Dong-Sheng Zhang, Zhi-Qiang Wang, Wen-Ting Liao, Lin Tian, Qi Zhao, Rui-Hua Xu
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nature medicine 30 (4) (2024)
Ying Jin, Run-Jie Huang, Wen-Long Guan, Zhi-Qiang Wang, Zong-Jiong Mai, Yu-Hong Li, Jian Xiao, Xing Zhang, Qi Zhao, Shi-Fu Chen, Ming Liu, Yan-Xia Shi, Feng-Hua Wang, Rui-Hua Xu
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation. Signal transduction and targeted therapy 9 (1) (2024)
Shixiang Wang, Chen-Yi Wu, Ming-Ming He, Jia-Xin Yong, Yan-Xing Chen, Li-Mei Qian, Jin-Ling Zhang, Zhao-Lei Zeng, Rui-Hua Xu, Feng-Hua Wang, Qi Zhao
Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer. Nature communications 15 (1) (2024)
Shu-Qiang Yuan, Run-Cong Nie, Ying Jin, Cheng-Cai Liang, Yuan-Fang Li, Rui Jian, Xiao-Wei Sun, Ying-Bo Chen, Wen-Long Guan, Zi-Xian Wang, Hai-Bo Qiu, Wei Wang, Shi Chen, Dong-Sheng Zhang, Yi-Hong Ling, Shao-Yan Xi, Mu-Yan Cai, Chun-Yu Huang, Qiu-Xia Yang, Zhi-Min Liu, Yuan-Xiang Guan, Yong-Ming Chen, Weiwei Xiao, Xiong-Wen Tang, Jun-Sheng Peng, Zhou-Wei Zhou, Rui-Hua Xu, Feng-Hua Wang
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nature medicine (2024)
Shu-Qiang Yuan, Run-Cong Nie, Ying Jin, Cheng-Cai Liang, Yuan-Fang Li, Rui Jian, Xiao-Wei Sun, Ying-Bo Chen, Wen-Long Guan, Zi-Xian Wang, Hai-Bo Qiu, Wei Wang, Shi Chen, Dong-Sheng Zhang, Yi-Hong Ling, Shao-Yan Xi, Mu-Yan Cai, Chun-Yu Huang, Qiu-Xia Yang, Zhi-Min Liu, Yuan-Xiang Guan, Yong-Ming Chen, Weiwei Xiao, Xiong-Wen Tang, Jun-Sheng Peng, Zhou-Wei Zhou, Rui-Hua Xu, Feng-Hua Wang
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nature medicine (2024)
Shu-Qiang Yuan, Run-Cong Nie, Ying Jin, Cheng-Cai Liang, Yuan-Fang Li, Rui Jian, Xiao-Wei Sun, Ying-Bo Chen, Wen-Long Guan, Zi-Xian Wang, Hai-Bo Qiu, Wei Wang, Shi Chen, Dong-Sheng Zhang, Yi-Hong Ling, Shao-Yan Xi, Mu-Yan Cai, Chun-Yu Huang, Qiu-Xia Yang, Zhi-Min Liu, Yuan-Xiang Guan, Yong-Ming Chen, Weiwei Xiao, Xiong-Wen Tang, Jun-Sheng Peng, Zhou-Wei Zhou, Rui-Hua Xu, Feng-Hua Wang
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nature medicine (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
Miao-Zhen Qiu, Do-Youn Oh, Ken Kato, Tobias Arkenau, Josep Tabernero, Marcia Cruz Correa, Anastasia V Zimina, Yuxian Bai, Jianhua Shi, Keun-Wook Lee, Jufeng Wang, Elena Poddubskaya, Hongming Pan, Sun Young Rha, Ruixing Zhang, Hidekazu Hirano, David Spigel, Kensei Yamaguchi, Yee Chao, Lucjan Wyrwicz, Umut Disel, Roberto Pazo Cid, Lorenzo Fornaro, Ludovic Evesque, Hongwei Wang, Yaling Xu, Jiang Li, Tao Sheng, Silu Yang, Liyun Li, Markus Moehler, Rui-Hua Xu, null null
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ (Clinical research ed.) 385 (2024)
Shu-Qiang Yuan, Run-Cong Nie, Ying Jin, Cheng-Cai Liang, Yuan-Fang Li, Rui Jian, Xiao-Wei Sun, Ying-Bo Chen, Wen-Long Guan, Zi-Xian Wang, Hai-Bo Qiu, Wei Wang, Shi Chen, Dong-Sheng Zhang, Yi-Hong Ling, Shao-Yan Xi, Mu-Yan Cai, Chun-Yu Huang, Qiu-Xia Yang, Zhi-Min Liu, Yuan-Xiang Guan, Yong-Ming Chen, Weiwei Xiao, Xiong-Wen Tang, Jun-Sheng Peng, Zhou-Wei Zhou, Rui-Hua Xu, Feng-Hua Wang
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nature medicine 30 (2) (2024)
Dan-Yun Ruan, Hao-Xiang Wu, Qi Meng, Rui-Hua Xu
Development of antibody-drug conjugates in cancer: Overview and prospects. Cancer communications (London, England) 44 (1) (2023)
Hong-En Yu, Feng Wang, Fang Yu, Zhao-Lei Zeng, Yun Wang, Yun-Xin Lu, Ying Jin, De-Shen Wang, Miao-Zheng Qiu, Heng-Ying Pu, Tie-Bang Kang, Dan Xie, Huai-Qiang Ju, Rui-Hua Xu, Hui-Yan Luo
Retraction Note: Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer. Cell death & disease 14 (1) (2023)
Wen Zhou, Ming-Ming He, Feng Wang, Rui-Hua Xu, Fang Wang, Qi Zhao
Latent class analysis-derived classification improves the cancer-specific death stratification of molecular subtyping in colorectal cancer. NPJ precision oncology 7 (1) (2023)
Jia Liu, Wei-Yi Zhou, Xiao-Jing Luo, Yan-Xing Chen, Chau-Wei Wong, Ze-Xian Liu, Jia- Bo Zheng, Hai- Yu Mo, Jun-Quan Chen, Jia-Jun Li, Ming Zhong, Yu-Hong Xu, Qi-Hua Zhang, Heng-Ying Pu, Qi-Nian Wu, Ying Jin, Zi-Xian Wang, Rui-Hua Xu, Hui-Yan Luo
Long noncoding RNA Regulating ImMune Escape regulates mixed lineage leukaemia protein-1-H3K4me3-mediated immune escape in oesophageal squamous cell carcinoma. Clinical and translational medicine 13 (9) (2023)
Jie-Feng Yang, Xudong Xing, Li Luo, Xin-Wei Zhou, Jian-Xiong Feng, Kang-Bo Huang, Huashan Liu, Shanzhao Jin, Yi-Na Liu, Shi-Hui Zhang, Yi-Hui Pan, Bing Yu, Jin-Yu Yang, Yu-Lu Cao, Yun Cao, Cliff Y Yang, Yuan Wang, Yuxia Zhang, Jiang Li, Xiaojun Xia, Tie-Bang Kang, Rui-Hua Xu, Ping Lan, Jun-Hang Luo, Hui Han, Fan Bai, Song Gao
Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8 + T cell metabolic fitness and function in tumors. Science immunology 8 (87) (2023)
Yongqiang Zheng, Yi-Qian Pan, Kun Liao, Kai Yu, Qinian Wu, Yanxing Chen, Yuqing Deng, Hui Sun, Hengying Pu, Huai-Qiang Ju, Rui-Hua Xu, Ze-Xian Liu
Pan-cancer landscape of tumour endothelial cells pinpoints insulin receptor as a novel antiangiogenic target and predicts immunotherapy response. Clinical and translational medicine 13 (12) (2023)
Bin Zhang, Chun-Mei Wang, Hao-Xiang Wu, Feng-Hua Wang, Yang-Yang Chai, Ye Hu, Bing-Jing Wang, Zhou Yu, Rong-Hua Xia, Rui-Hua Xu, Xue-Tao Cao
MFSD2A potentiates gastric cancer response to anti-PD-1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response. Cancer communications (London, England) (2023)
Miao-Zheng Qiu, Chaoye Wang, Zhiying Wu, Qi Zhao, Zhibin Zhao, Chun-Yu Huang, Wenwei Wu, Li-Qiong Yang, Zhi-Wei Zhou, Yu Zheng, Hong-Ming Pan, Ze-Xian Liu, Zhao-Lei Zeng, Hui-Yan Luo, Feng Wang, Feng-Hua Wang, Si-Yu Yang, Meng-Xing Huang, Zhe-Xiong Lian, Haiyan Zhang, Rui-Hua Xu
Dynamic single-cell mapping unveils Epstein‒Barr virus-imprinted T-cell exhaustion and on-treatment response. Signal transduction and targeted therapy 8 (1) (2023)
Shu-Qiang Yuan, Run-Cong Nie, You-Sheng Huang, Ying-Bo Chen, Si-Yu Wang, Xiao-Wei Sun, Yuan-Fang Li, Ze-Kun Liu, Yan-Xing Chen, Yi-Chen Yao, Yu Xu, Hai-Bo Qiu, Yao Liang, Wei Wang, Ze-Xian Liu, Qi Zhao, Rui-Hua Xu, Zhi-Wei Zhou, Feng-Hua Wang
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer. Cancer communications (London, England) (2023)
Dan-Yun Ruan, Hao-Xiang Wu, Qi Meng, Rui-Hua Xu
Development of antibody-drug conjugates in cancer: Overview and prospects. Cancer communications (London, England) 44 (1) (2023)
Feng-Hua Wang, Xiao-Tian Zhang, Lei Tang, Qi Wu, Mu-Yan Cai, Yuan-Fang Li, Xiu-Juan Qu, Hong Qiu, Yu-Jing Zhang, Jie-Er Ying, Jun Zhang, Ling-Yu Sun, Rong-Bo Lin, Chang Wang, Hao Liu, Miao-Zheng Qiu, Wen-Long Guan, Sheng-Xiang Rao, Jia-Fu Ji, Yan Xin, Wei-Qi Sheng, Hui-Mian Xu, Zhi-Wei Zhou, Ai-Ping Zhou, Jing Jin, Xiang-Lin Yuan, Feng Bi, Tian-Shu Liu, Han Liang, Yan-Qiao Zhang, Guo-Xin Li, Jun Liang, Bao-Rui Liu, Lin Shen, Jin Li, Rui-Hua Xu
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer communications (London, England) (2023)
Wen Zhou, Ming-Ming He, Feng Wang, Rui-Hua Xu, Fang Wang, Qi Zhao
Publisher Correction: Latent class analysis-derived classification improves the cancer-specific death stratification of molecular subtyping in colorectal cancer. NPJ precision oncology 7 (1) (2023)
Feng-Hua Wang, Xiao-Tian Zhang, Lei Tang, Qi Wu, Mu-Yan Cai, Yuan-Fang Li, Xiu-Juan Qu, Hong Qiu, Yu-Jing Zhang, Jie-Er Ying, Jun Zhang, Ling-Yu Sun, Rong-Bo Lin, Chang Wang, Hao Liu, Miao-Zheng Qiu, Wen-Long Guan, Sheng-Xiang Rao, Jia-Fu Ji, Yan Xin, Wei-Qi Sheng, Hui-Mian Xu, Zhi-Wei Zhou, Ai-Ping Zhou, Jing Jin, Xiang-Lin Yuan, Feng Bi, Tian-Shu Liu, Han Liang, Yan-Qiao Zhang, Guo-Xin Li, Jun Liang, Bao-Rui Liu, Lin Shen, Jin Li, Rui-Hua Xu
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer communications (London, England) 44 (1) (2023)
Dan-Yun Ruan, Hao-Xiang Wu, Qi Meng, Rui-Hua Xu
Development of antibody-drug conjugates in cancer: Overview and prospects. Cancer communications (London, England) 44 (1) (2023)
Manish A Shah, Kohei Shitara, Jaffer A Ajani, Yung-Jue Bang, Peter Enzinger, David Ilson, Florian Lordick, Eric Van Cutsem, Javier Gallego Plazas, Jing Huang, Lin Shen, Sang Cheul Oh, Patrapim Sunpaweravong, Hwoei Fen Soo Hoo, Haci Mehmet Turk, Mok Oh, Jung Wook Park, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Rui-Hua Xu
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nature medicine (2023)
Feng-Hua Wang, Xiao-Tian Zhang, Lei Tang, Qi Wu, Mu-Yan Cai, Yuan-Fang Li, Xiu-Juan Qu, Hong Qiu, Yu-Jing Zhang, Jie-Er Ying, Jun Zhang, Ling-Yu Sun, Rong-Bo Lin, Chang Wang, Hao Liu, Miao-Zheng Qiu, Wen-Long Guan, Sheng-Xiang Rao, Jia-Fu Ji, Yan Xin, Wei-Qi Sheng, Hui-Mian Xu, Zhi-Wei Zhou, Ai-Ping Zhou, Jing Jin, Xiang-Lin Yuan, Feng Bi, Tian-Shu Liu, Han Liang, Yan-Qiao Zhang, Guo-Xin Li, Jun Liang, Bao-Rui Liu, Lin Shen, Jin Li, Rui-Hua Xu
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer communications (London, England) 44 (1) (2023)
Jia-Jun Li, Jin-Hong Wang, Tian Tian, Jia Liu, Yong-Qiang Zheng, Hai-Yu Mo, Hui Sheng, Yan-Xing Chen, Qi-Nian Wu, Yi Han, Kun Liao, Yi-Qian Pan, Zhao-Lei Zeng, Ze-Xian Liu, Wei Yang, Rui-Hua Xu, Huai-Qiang Ju
The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer. Nature communications 14 (1) (2023)
Hong-En Yu, Feng Wang, Fang Yu, Zhao-Lei Zeng, Yun Wang, Yun-Xin Lu, Ying Jin, De-Shen Wang, Miao-Zheng Qiu, Heng-Ying Pu, Tie-Bang Kang, Dan Xie, Huai-Qiang Ju, Rui-Hua Xu, Hui-Yan Luo
Retraction Note: Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer. Cell death & disease 14 (1) (2023)
Feng-Hua Wang, Xiao-Tian Zhang, Lei Tang, Qi Wu, Mu-Yan Cai, Yuan-Fang Li, Xiu-Juan Qu, Hong Qiu, Yu-Jing Zhang, Jie-Er Ying, Jun Zhang, Ling-Yu Sun, Rong-Bo Lin, Chang Wang, Hao Liu, Miao-Zheng Qiu, Wen-Long Guan, Sheng-Xiang Rao, Jia-Fu Ji, Yan Xin, Wei-Qi Sheng, Hui-Mian Xu, Zhi-Wei Zhou, Ai-Ping Zhou, Jing Jin, Xiang-Lin Yuan, Feng Bi, Tian-Shu Liu, Han Liang, Yan-Qiao Zhang, Guo-Xin Li, Jun Liang, Bao-Rui Liu, Lin Shen, Jin Li, Rui-Hua Xu
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer communications (London, England) 44 (1) (2023)
Dan-Yun Ruan, Hao-Xiang Wu, Qi Meng, Rui-Hua Xu
Development of antibody-drug conjugates in cancer: overview and prospects. Cancer communications (London, England) (2023)
Dandan Li, Chao Chen, Jingjing Li, Jianhui Yue, Ya Ding, Hailun Wang, Zhaoduan Liang, Le Zhang, Si Qiu, Geng Liu, Yan Gao, Ying Huang, Dongli Li, Rong Zhang, Wei Liu, Xizhi Wen, Bo Li, Xiao-Shi Zhang, Xi Zhang, Rui-Hua Xu
A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors. Nature communications 14 (1) (2023)
Shu-Kui Qin, Jin Li, Yuxian Bai, Zishu Wang, Zhendong Chen, Rui-Hua Xu, Jian-Ming Xu, Hong-Mei Zhang, Jia Chen, Ying Yuan, Tianshu Liu, Lin Yang, Haijun Zhong, Donghui Chen, Lin Shen, Chunyi Hao, Deliang Fu, Ying Cheng, Jianwei Yang, Qiong Wang, Baoli Qin, Hongming Pan, Jun Zhang, Xianhong Bai, Qingshan Zheng
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Tian-Shu Liu, Yuxian Bai, Xiaoyan Lin, Wei Li, Jufeng Wang, Xiaochun Zhang, Hongming Pan, Chun-Mei Bai, Li Bai, Ying Cheng, Jingdong Zhang, Haijun Zhong, Yi Ba, Wenwei Hu, Rui-Hua Xu, Weijian Guo, Shukui Qin, Nong Yang, Jianwei Lu, Kohei Shitara, Ming Lei, Mingshun Li, Nicole Bao, Tian Chen, Lin Shen
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis. International journal of cancer (2022)
Manish A Shah, Kohei Shitara, Florian Lordick, Yung-Jue Bang, Niall C Tebbutt, Jean-Phillippe Metges, Kei Muro, Keun-Wook Lee, Lin Shen, Sergei Tjulandin, John L Hays, Naureen Starling, Rui-Hua Xu, Keren Sturtz, Marilyn Fontaine, Cindy Oh, Emily Brooks, Bo Xu, Wei Li, Chiang J Li, Laura Borodyansky, Eric Van Cutsem
Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Yan-Xing Chen, Zi-Xian Wang, Shu-Qiang Yuan, Teng-Jia Jiang, You-Sheng Huang, Rui-Hua Xu, Feng-Hua Wang, Qi Zhao
POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy. Clinical and translational medicine 11 (9) (2022)
Hao-Xiang Wu, Yi-Qian Pan, Ye He, Zi-Xian Wang, Wen-Long Guan, Yan-Xing Chen, Yi-Chen Yao, Ning-Yi Shao, Rui-Hua Xu, Feng-Hua Wang
Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Jia Liu, Ze-Xian Liu, Jia-Jun Li, Zhao-Lei Zeng, Jin-Hong Wang, Xiao-Jing Luo, Chau-Wei Wong, Jia Bo Zheng, Heng-Ying Pu, Hai-Yu Mo, Hui Sheng, Qi-Nian Wu, Hao Li, Gang Wan, Bo Li, De-Sheng Wang, Rui-Hua Xu, Huai-Qiang Ju
The macrophage-associated lncRNA MALR facilitates ILF3 liquid-liquid phase separation to promote HIF1α signaling in esophageal cancer. Cancer research (2022)
Manish A Shah, Kohei Shitara, Florian Lordick, Yung-Jue Bang, Niall C Tebbutt, Jean-Phillippe Metges, Kei Muro, Keun-Wook Lee, Lin Shen, Sergei Tjulandin, John L Hays, Naureen Starling, Rui-Hua Xu, Keren Sturtz, Marilyn Fontaine, Cindy Oh, Emily M Brooks, Bo Xu, Wei Li, Chiang J Li, Laura Borodyansky, Eric Van Cutsem
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Yang Zhang, Zi-Xian Wang, Lin Shen, Jin Li, Jing Huang, Wei-Guo Su, Dong-Sheng Zhang, Rui-Hua Xu
A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer. Cancer communications (London, England) (2022)
Kai Yu, Ye Wang, Yong-Qiang Zheng, Zekun Liu, Qingfeng Zhang, Siyu Wang, Qi Zhao, Xiaolong Zhang, Xiaoxing Li, Rui-Hua Xu, Ze-Xian Liu
qPTM: an updated database for PTM dynamics in human, mouse, rat and yeast. Nucleic acids research (2022)
Xiao-Jing Luo, Ming-Ming He, Jia Liu, Jia-Bo Zheng, Qi-Nian Wu, Yan-Xing Chen, Qi Meng, Kong-Jia Luo, Dong-Liang Chen, Rui-Hua Xu, Zhao-Lei Zeng, Ze-Xian Liu, Hui-Yan Luo
LncRNA TMPO-AS1 promotes esophageal squamous cell carcinoma progression by forming biomolecular condensates with FUS and p300 to regulate TMPO transcription. Experimental & molecular medicine 54 (6) (2022)
Qi Zhao, Feng Wang, Yan-Xing Chen, Shifu Chen, Yi-Chen Yao, Zhao-Lei Zeng, Teng-Jia Jiang, Ying-Nan Wang, Chen-Yi Wu, Ying Jing, You-Sheng Huang, Jing Zhang, Zi-Xian Wang, Ming-Ming He, Heng-Ying Pu, Zong-Jiong Mai, Qi-Nian Wu, Renwen Long, Xiaoni Zhang, Tanxiao Huang, Mingyan Xu, Miao-Zheng Qiu, Hui-Yan Luo, Yu-Hong Li, Dong-Shen Zhang, Wei-Hua Jia, Gong Chen, Pei-Rong Ding, Li-Ren Li, Zheng-Hai Lu, Zhi-Zhong Pan, Rui-Hua Xu
Comprehensive profiling of 1015 patients' exomes reveals genomic-clinical associations in colorectal cancer. Nature communications 13 (1) (2022)
Feng-Hua Wang, Ming-Ming He, Jian Xiao, Yan-Qiao Zhang, Xiang-Lin Yuan, Wei-Jia Fang, Yan Zhang, Wei Wang, Xiao-Hua Hu, Zhi-Gang Ma, Yi-Chen Yao, Zhi-Xiang Zhuang, Yingying Shi, Jie-Er Ying, Ying Yuan, Qing-Feng Zou, Zeng Qing Guo, Xiang-Yuan Wu, Ying Jin, Zong-Jiong Mai, Zhi-Qiang Wang, Hong Qiu, Ying Guo, Si-Mei Shi, Shuang-Zhen Chen, Hui-Yan Luo, Dong-Sheng Zhang, Feng-Hua Wang, Yu-Hong Li, Rui-Hua Xu
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study). Clinical cancer research : an official journal of the American Association for Cancer Research 28 (19) (2022)
Ying-Nan Wang, Dan-Yun Ruan, Zi-Xian Wang, Kai Yu, Dai-Lin Rong, Ze-Xian Liu, Feng-Hua Wang, Jia-Jia Hu, Ying Jin, Qi-Nian Wu, Heng-Ying Pu, Min Wang, Rui-Hua Xu, Zhao-Lei Zeng
Targeting the cholesterol-RORα/γ axis inhibits colorectal cancer progression through degrading c-myc. Oncogene 41 (49) (2022)
Jin-Fei Lin, Pei-Shan Hu, Yi-Yu Wang, Yue-Tao Tan, Kai Yu, Kun Liao, Qi-Nian Wu, Ting Li, Qi Meng, Jun-Zhong Lin, Ze-Xian Liu, Heng-Ying Pu, Huai-Qiang Ju, Rui-Hua Xu, Miao-Zheng Qiu
Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis. Signal transduction and targeted therapy 7 (1) (2022)
Qi Meng, Yun-Xin Lu, Chen Wei, Zi-Xian Wang, Jin-Fei Lin, Kun Liao, Xiao-Jing Luo, Kai Yu, Yi Han, Jia-Jun Li, Yue-Tao Tan, Hao Li, Zhao-Lei Zeng, Bo Li, Rui-Hua Xu, Huai-Qiang Ju
Arginine methylation of MTHFD1 by PRMT5 enhances anoikis resistance and cancer metastasis. Oncogene 41 (32) (2022)
Rui-Hua Xu, Yang Zhang, Hong-Yun Zhao, Wen-Feng Fang, Hui-Yan Luo, Miao-Zhen Qiu, Ming-Ming He, Ben-Yan Zou, Jie Xie, Chun-Lei Jin, Xian-Feng Zhou, Feng Wang, Feng-Hua Wang, Yu-Hong Li, Zhi-Qiang Wang, Rui-Hua Xu
Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials. The oncologist (2022)
Xiao-Li Wei, Fu-Rong Liu, Ji-Hong Liu, Hong-Yun Zhao, Yang Zhang, Zhi-Qiang Wang, Miao-Zheng Qiu, Fei Xu, Qiu-Qiong Yu, Yi-Wu Du, Yan-Xia Shi, De-Sheng Wang, Feng-Hua Wang, Rui-Hua Xu
First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors. Nature communications 13 (1) (2022)
Zhao-Lei Zeng, Jia-Huan Lu, Yun Wang, Hui Sheng, Ying-Nan Wang, Zhan-Hong Chen, Qi-Nian Wu, Jia-Bo Zheng, Yan-Xing Chen, Dong-Dong Yang, Kai Yu, Hai-Yu Mo, Jia-Jia Hu, Pei-Shan Hu, Ze-Xian Liu, Huai-Qiang Ju, Rui-Hua Xu
The lncRNA XIST/miR-125b-2-3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer. Cancer medicine 10 (7) (2021)
Hai-Bo Qiu, Sumei Cao, Rui-Hua Xu
Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer communications (London, England) 41 (10) (2021)
Zi-Xian Wang, Hao-Xiang Wu, Li Xie, Wu-Hao Lin, Fei Liang, Jin Li, Zhi-Min Yang, Rui-Hua Xu
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials. Journal for immunotherapy of cancer 9 (4) (2021)
Dan-Yun Ruan, Yan-Xing Chen, Xiao-Li Wei, Ying-Nan Wang, Zi-Xian Wang, Hao-Xiang Wu, Rui-Hua Xu, Shu-Qiang Yuan, Feng-Hua Wang
Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer. Gastroenterology report 9 (6) (2021)
Hui-Yan Luo, Qi Zhao, Wei Wei, Lianghong Zheng, Shaohua Yi, Gen Li, Wenqiu Wang, Hui Sheng, Hengying Pu, Haiyu Mo, Zhi-Xiang Zuo, Ze-Xian Liu, Chaofeng Li, Chuanbo Xie, Zhao-Lei Zeng, Wei-Min Li, Xiaoke Hao, Yuying Liu, Sumei Cao, Wanli Liu, Sarah Gibson, Kang Zhang, Guoliang Xu, Rui-Hua Xu
Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Science translational medicine 12 (524) (2021)
Dan-Yun Ruan, Ting Li, Ying-Nan Wang, Qi Meng, Yang Li, Kai Yu, Min Wang, Jin-Fei Lin, Li-Zhi Luo, De-Shen Wang, Jun-Zhong Lin, Long Bai, Ze-Xian Liu, Qi Zhao, Xiang-Yuan Wu, Huai-Qiang Ju, Rui-Hua Xu
FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis. Oncogene 40 (33) (2021)
Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, Ying-Rui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu, Ping Li, Chunhong Hu, Yi-Chun Liu, Yi Jiang, Xia He, Hung-Ming Wang, Darren Wan-Teck Lim, Wangjun Liao, Xiaohui He, Xiaozhong Chen, Zhi-Gang Liu, Xianglin Yuan, Qi Li, Xiaoyan Lin, Shanghua Jing, Yanju Chen, Yin Lu, Ching-Yun Hsieh, Muh-Hwa Yang, Chia-Jui Yen, Jens Samol, Hui Feng, Sheng Yao, Patricia Keegan, Rui-Hua Xu
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nature medicine 27 (9) (2021)
Feng-Hua Wang, Xiao-Li Wei, Jifeng Feng, Qi Li, Nong Xu, Xi-Chun Hu, Wangjun Liao, Yi Jiang, Xiao-Yan Lin, Qing-Yuan Zhang, Xiang-Lin Yuan, Hai-Xin Huang, Ye Chen, Guang-Hai Dai, Jian-Hua Shi, Lin Shen, Shu-Jun Yang, Yong-Qian Shu, Yun-Peng Liu, Weifeng Wang, Hai Wu, Hui Feng, Sheng Yao, Rui-Hua Xu
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (7) (2021)
Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu
Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of hematology & oncology 14 (1) (2021)
Jie-Ying Liang, Hao-Cheng Lin, Jingwen Liu, De-Sheng Wang, Yun-Fei Yuan, Bin-Kui Li, Yun Zheng, Xiao-Jun Wu, Gong Chen, Feng-Hua Wang, Zhi-Qiang Wang, Zhi-Zhong Pan, De-Sen Wan, Rui-Hua Xu, Yu-Hong Li
A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy. Cancer medicine 10 (5) (2021)
Yun Wang, Min Wang, Hao-Xiang Wu, Rui-Hua Xu
Advancing to the era of cancer immunotherapy. Cancer communications (London, England) 41 (9) (2021)
Zi-Hang Chen, Li Lin, Chen-Fei Wu, Chao-Feng Li, Rui-Hua Xu, Yuyao Sun
Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine. Cancer communications (London, England) 41 (11) (2021)
Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu
Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut (2021)
Feng Wang, Zi-Xian Wang, Gong Chen, Hui-Yan Luo, Dong-Sheng Zhang, Miao-Zheng Qiu, De-Shen Wang, Zhi-Zhong Pan, Lin Shen, Jin Li, Su-Zhan Zhang, Rui-Hua Xu
Expert opinions on immunotherapy for patients with colorectal cancer. Cancer communications (London, England) 40 (10) (2020)
Wei-Yi Zhou, Ze-Rong Cai, Jia Liu, De-Shen Wang, Huai-Qiang Ju, Rui-Hua Xu
Circular RNA: metabolism, functions and interactions with proteins. Molecular cancer 19 (1) (2020)
Ming-Ming He, Zhe Fang, Dong Hang, Feng-Hua Wang, Georgios Polychronidis, Liang Wang, Chun-Han Lo, Kai Wang, Rong Zhong, Markus D Knudsen, Scott G Smith, Rui-Hua Xu, Mingyang Song
Circulating liver function markers and colorectal cancer risk: A prospective cohort study in the UK Biobank. International journal of cancer 148 (8) (2020)
Pei-Shan Hu, Ting Li, Jin-Fei Lin, Miao-Zhen Qiu, De-Shen Wang, Ze-Xian Liu, Zhan-Hong Chen, Lu-Ping Yang, Xiao-Long Zhang, Qi Zhao, Yan-Xing Chen, Yun-Xin Lu, Qi-Nian Wu, Heng-Ying Pu, Zhao-Lei Zeng, Dan Xie, Huai-Qiang Ju, Hui-Yan Luo, Rui-Hua Xu
VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal transduction and targeted therapy 5 (1) (2020)
Huai-Qiang Ju, Jin-Fei Lin, Tian Tian, Dan Xie, Rui-Hua Xu
NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal transduction and targeted therapy 5 (1) (2020)
Jia Liu, Ze-Xian Liu, Qi-Nian Wu, Yun-Xin Lu, Chau-Wei Wong, Lei Miao, Yun Wang, Zixian Wang, Ying Jin, Ming-Ming He, Chao Ren, De-Shen Wang, Dong-Liang Chen, Heng-Ying Pu, Lin Feng, Bo Li, Dan Xie, Mu-Sheng Zeng, Peng Huang, Aifu Lin, Dongxin Lin, Rui-Hua Xu, Huai-Qiang Ju
Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nature communications 11 (1) (2020)
Hong-En Yu, Feng Wang, Fang Yu, Zhao-Lei Zeng, Yun Wang, Yun-Xin Lu, Ying Jin, De-Shen Wang, Miao-Zheng Qiu, Heng-Ying Pu, Tie-Bang Kang, Dan Xie, Huai-Qiang Ju, Rui-Hua Xu, Hui-Yan Luo
Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer. Cell death & disease 10 (6) (2019)
Feng Wang, Ming-Ming He, Zi-Xian Wang, Su Li, Ying Jin, Chao Ren, Si-Mei Shi, Bing-Tian Bi, Shuang-Zhen Chen, Zhi-Da Lv, Jia-Jia Hu, Zhi-Qiang Wang, Feng-Hua Wang, De-Shen Wang, Yu-Hong Li, Rui-Hua Xu
Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. BMC cancer 19 (1) (2019)
Miao Xu, Youyuan Yao, Hui Chen, Shanshan Zhang, Su-Mei Cao, Zhe Zhang, Bing Luo, Zhiwei Liu, Zilin Li, Tong Xiang, Guiping He, Qi-Sheng Feng, Li-Zhen Chen, Xiang Guo, Wei-Hua Jia, Ming-Yuan Chen, Xiao Zhang, Shang-Hang Xie, Roujun Peng, Ellen T Chang, Vincent Pedergnana, Lin Feng, Jin-Xin Bei, Rui-Hua Xu, Mu-Sheng Zeng, Weimin Ye, Hans-Olov Adami, Xihong Lin, Weiwei Zhai, Yi-Xin Zeng, Jian-Jun Liu
Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nature genetics 51 (7) (2019)
Ying-Nan Wang, Yun-Xin Lu, Jie Liu, Ying Jin, Hui-Chang Bi, Qi Zhao, Ze-Xian Liu, Ying-Qin Li, Jia-Jia Hu, Hui Sheng, Yi-Ming Jiang, Chao Zhang, Feng Tian, Yang Chen, Zhi-Zhong Pan, Gong Chen, Zhao-Lei Zeng, Kai-Yan Liu, Marcia Ogasawara, Jin-Ping Yun, Huai-Qiang Ju, Jian-Xiong Feng, Dan Xie, Song Gao, Wei-Hua Jia, Scott Kopetz, Rui-Hua Xu, Feng Wang
AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. Oncogene 39 (3) (2019)
De-Sheng Wang, Zhi-Qiang Wang, Gong Chen, Jie-Wen Peng, Wei Wang, Yan-Hong Deng, Feng-Hua Wang, Jian-Wei Zhang, Han-Lin Liang, Fen Feng, Chuan-Bo Xie, Chao Ren, Ying Jin, Si-Mei Shi, Wen-Hua Fan, Zhen-Hai Lu, Pei-Rong Ding, Feng Wang, Rui-Hua Xu, Yu-Hong Li
Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. Cancer medicine 9 (1) (2019)
Yun Wang, Xiao-Qiang Sun, Hao-Cheng Lin, De-Shen Wang, Zhi-Qiang Wang, Qiong Shao, Feng-Hua Wang, Shu-Mei Yan, Jie-Ying Liang, Zhao-Lei Zeng, Huai-Qiang Ju, Rui-Hua Xu, Yu-Hong Li
Correlation between immune signature and high-density lipoprotein cholesterol level in stage II/III colorectal cancer. Cancer medicine 8 (3) (2019)
Hao-Xiang Wu, Yan-Xing Chen, Zi-Xian Wang, Qi Zhao, Ming-Ming He, Ying-Nan Wang, Feng Wang, Rui-Hua Xu
Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. Journal for immunotherapy of cancer 7 (1) (2019)
Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu
LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular cancer 18 (1) (2019)
Ting Li, Pei-Shan Hu, Zhixiang Zuo, Jin-Fei Lin, Xingyang Li, Qi-Nian Wu, Zhan-Hong Chen, Zhao-Lei Zeng, Feng Wang, Jian Zheng, Demeng Chen, Bo Li, Tie-Bang Kang, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma. Molecular cancer 18 (1) (2019)
Huai-Qiang Ju, Qi Zhao, Feng Wang, Ping Lan, Zixian Wang, Zhi-Xiang Zuo, Qi-Nian Wu, Xin-Juan Fan, Hai-Yu Mo, Li Chen, Ting Li, Chao Ren, Xiang-Bo Wan, Gong Chen, Yu-Hong Li, Wei-Hua Jia, Rui-Hua Xu
A circRNA signature predicts postoperative recurrence in stage II/III colon cancer. EMBO molecular medicine 11 (10) (2019)
Ri-Xin Chen, Xin Chen, Liang-Ping Xia, Jia-Xing Zhang, Zhi-Zhong Pan, Xiao-Dan Ma, Kai Han, Jie-Wei Chen, Jean-Gabrie Judde, Olivier Deas, Feng Wang, Ning-Fang Ma, Xinyuan Guan, Jing-Ping Yun, Feng-Wei Wang, Rui-Hua Xu, Dan Xie
N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. Nature communications 10 (1) (2019)
Hao-Xiang Wu, Zi-Xian Wang, Qi Zhao, Feng Wang, Rui-Hua Xu
Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'. Journal for immunotherapy of cancer 7 (1) (2019)

Rui-Hua Xu.css-eqlu8i{font-size:small;padding-left:4px;} (Ruihua Xu)

Publication Activity (10 Years)

Top Topics

Top Venues

Rui-Hua Xu (Ruihua Xu)